Journal of Dermatological Treatment最新文献

{"title":"Initial validation of a new device for facial skin analysis.","authors":"Madison K Cook,&nbsp;Margaret A Kaszycki,&nbsp;Irma Richardson,&nbsp;Sarah L Taylor,&nbsp;Steven R Feldman","doi":"10.1080/09546634.2022.2127305","DOIUrl":"https://doi.org/10.1080/09546634.2022.2127305","url":null,"abstract":"<p><p>The field of dermatology is met with many subjective analysis methods. Due to the relative nature of subjective analysis methods, objective analysis methods with greater accuracy and reliability were developed. Many of these devices are either inaccessible to patients without being a part of a clinical trial, bulky, or costly. However, with the advances in artificial intelligence and handheld devices, measurement methods have become simplified. The purpose of our study was to validate an objective skin analysis software available on a handheld device by comparing it to a board-certified dermatologist's assessment. Participants of various ages and skin types were analyzed with the facial analysis system on an iPad Pro. The same photographs were ranked by a physician based on 14 common skin characteristics. The facial analysis system and the physician's rankings had a good agreement rate of 69%. The greatest agreement rates were with the assessment of erythema (83.7%) and wrinkles (81.6%) and the lowest with oiliness (53.1%). The analysis system's high re-test reliability and good agreement rates with physician assessment support its potential use in the clinical setting.</p>","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3150-3153"},"PeriodicalIF":2.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10411095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social media voices on the treatment of skin psoriasis with biologics.","authors":"Melissa A Nickles,&nbsp;Roger N Haber","doi":"10.1080/09546634.2022.2126276","DOIUrl":"https://doi.org/10.1080/09546634.2022.2126276","url":null,"abstract":"<p><p>Social media is an outlet for patients to share medical experiences with a large audience. However, the impact of such content on individual patient treatment decisions has yet to be fully explored. We characterized patient experiences posted on social media surrounding biologic use for skin psoriasis. We analyzed content from YouTube, Instagram, and TikTok and identified patient experiences with a variety of biologics, most commonly Humira (20.7%), Cosentyx (14.0%), and Stelara (14.0%). The biologic was described as burdensome in about half of all videos/posts (46.4%), and the most commonly cited reasons included adverse effects or abnormal blood tests (12.8%), cost or insurance issues (11.7%), lack or loss of efficacy (11.7%), and pain with injection or injection site reaction (11.7%). Nevertheless, the majority (60.9%) of videos/posts reported an overall positive experience with a biologic for their skin psoriasis, which may inspire reluctant patients to try a biologic recommended by their physician.</p>","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3208-3209"},"PeriodicalIF":2.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10415297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe papulopustular rosacea successfully treated with a combination of oral azithromycin and isotretinoin.","authors":"Hans Christian Ring,&nbsp;Claus Zachariae,&nbsp;Simon Francis Thomsen,&nbsp;Jacob P Thyssen,&nbsp;Alexander Egeberg","doi":"10.1080/09546634.2022.2129953","DOIUrl":"https://doi.org/10.1080/09546634.2022.2129953","url":null,"abstract":"<p><p>Papulopustular rosacea is notoriously a challenge to treat, and treatment options are scarce. Only limited data exist on the use of azithromycin in treatment of papulopustular rosacea. However, the unique pharmacokinetics of azithromycin may have several indications in the treatment of papulopustular rosacea. We here report a case of hard-to-treat papulopustular rosacea which was successfully treated with pulsed oral azithromycin in addition to maintenance isotretinoin.</p>","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3205-3207"},"PeriodicalIF":2.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10411812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methotrexate dosing regimen for plaque-type psoriasis: an update of a systematic review.","authors":"Astrid M van Huizen,&nbsp;Rosie Sikkel,&nbsp;Anouk G M Caron,&nbsp;Stef P Menting,&nbsp;Phyllis I Spuls","doi":"10.1080/09546634.2022.2117539","DOIUrl":"https://doi.org/10.1080/09546634.2022.2117539","url":null,"abstract":"<p><strong>Background: </strong>Methotrexate (MTX) is a systemic treatment for plaque-type psoriasis. At the time of approval, no dose-ranging studies were performed. Nowadays, a uniform dosing regimen is lacking. This might contribute to suboptimal treatment with the drug.</p><p><strong>Objective: </strong>To summarize the literature involving the MTX dosing regimens in psoriasis patients.</p><p><strong>Methods: </strong>In this SR, RCTs and documents with aggregated evidence (AgEv) on the MTX dosing regimen in psoriasis were summarized. All randomized controlled trials (RCTs) in which oral, subcutaneous or intramuscular MTX was used in patients with psoriasis and AgEv, were included. The MEDLINE, EMBASE and CENTRAL databases were searched up to June 20, 2022. This SR was registered in PROSPERO.</p><p><strong>Results: </strong>Thirty-nine RCTs had a high risk of bias. Test dosages were given in only 3 RCTs. In the RCTs, MTX was usually prescribed in a start dose of 7.5 mg/week (<i>n</i> = 13). MTX was mostly given in a start dose of 15 mg/week, in the AgEv (<i>n</i> = 5). One guideline recommended a test dose, in other aggregated evidence a test dose was not mentioned or even discouraged.</p><p><strong>Conclusions: </strong>There is a lack of high-quality evidence and available data for dosing MTX in psoriasis is heterogeneous.</p>","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3104-3118"},"PeriodicalIF":2.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10776536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of lasers in treating syringomas: a review of the literature.","authors":"Mohammed Saud Alsaidan","doi":"10.1080/09546634.2022.2127307","DOIUrl":"https://doi.org/10.1080/09546634.2022.2127307","url":null,"abstract":"<p><p>Syringomas are benign adnexal neoplasms that may induce psychological stress when they are large or disfiguring or present in delicate regions such as the periorbital area. Despite the availability of various lasers for syringomas, no consensus has been established on the optimal laser setting and side effects of these therapies. The current review aims at understanding the efficacy and safety of various laser therapies available for the treatment of syringomas. A literature search was carried out using PubMed and Ovid databases for articles published from Jan 2000 through Mar 2022. Screening the eligible articles yielded 27 studies, comprising clinical studies, case series, and case reports, which were included in this review. The CO₂ laser is the most widely used ablative laser therapy but is usually associated with adverse events. Pinhole and multiple drilling methods using CO₂ laser yielded excellent cosmetic results with minimal adverse effects. Fractional lasers reduced the downtime and complications compared to non-fractionated ones. Non-ablative fractional lasers could be advantageous in terms of easy operation, minimal side effects and moderate recovery period compared with ablative lasers. Large clinical trials are needed to generate strong evidence to guide clinicians in choosing the most appropriate laser therapy for syringoma treatment.</p>","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3127-3135"},"PeriodicalIF":2.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10402647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psoriasis: is it a risk factor for cardiovascular diseases?","authors":"Hesham Nada,&nbsp;Attef Elakhrass,&nbsp;Neven Ahmad,&nbsp;Mohamed Refaat","doi":"10.1080/09546634.2022.2112137","DOIUrl":"https://doi.org/10.1080/09546634.2022.2112137","url":null,"abstract":"<p><strong>Background/objectives: </strong>Psoriasis, newly considered as a systemic inflammatory condition, has a high prevalence of cardiovascular diseases (CVDs), including atherosclerosis and myocardial infarction. Measurement of carotid artery intima-media thickness (C-IMT) represents a noninvasive diagnostic tool for predicting cardiovascular disorders. We aimed to determine if psoriatic patients have an increased risk for the development of cardiovascular disorders by assessment of the presence of subclinical atherosclerosis in psoriasis patients.</p><p><strong>Methods: </strong>Forty adult psoriatic patients and 40 matched healthy controls were selected in this study. All participants were subjected to full history, examination, assessment of the severity of psoriasis using psoriasis area and severity index (PASI) score, measuring serum lipid profile (cholesterol, low density lipoprotein (LDL) and triglycerides) and C-IMT.</p><p><strong>Results: </strong>Psoriatic patients showed significantly higher serum lipid profile findings and C-IMT. There was a positive statistically significant correlation between C-IMT and each of age of the patients (<i>r</i> = 0.760, <i>p</i><.001) and severity of psoriasis (PASI score).</p><p><strong>Conclusions: </strong>There is increased susceptibility to CVDs in psoriatic patients represented by increased incidence of subclinical atherosclerosis and dyslipidemia in our patients.</p>","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3154-3159"},"PeriodicalIF":2.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10414210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Koo-Brownstone staging system as a tool to assist in the management of patients with a possible diagnosis of dermatological delusions: an experts suggestion.","authors":"Nicholas Brownstone,&nbsp;John Koo","doi":"10.1080/09546634.2022.2112548","DOIUrl":"https://doi.org/10.1080/09546634.2022.2112548","url":null,"abstract":"<p><strong>Background: </strong>Delusional infestation (DI) is one of the most challenging situations dermatologists and other dermatology providers may face in their practice. Dermatologists must know how to properly communicate with these patients. The process of acquiring delusional states can be a gradual development and not all delusional patients in dermatology are the same.</p><p><strong>Objective: </strong>The objective of this manuscript is to introduce the 'Koo-Brownstone Staging System' for Delusional Infestation (Morgellons disease) with the goal of improving communication and management for these patients.</p><p><strong>Methods: </strong>This staging system has been derived based on more than three decades of experience of the senior author supported by additional years of experience of the first author.</p><p><strong>Results: </strong>The following stages are presented and explained: formication only (stage 1), overvalued ideation of parasitosis (stage 2), pre-delusional (stage 3), delusional (stage 4) and terminally delusional (stage 5).</p><p><strong>Limitations: </strong>This staging system has been derived based on expert clinical experience rather than a direct reporting from this patient population themselves.</p><p><strong>Conclusions: </strong>This staging system will enhance awareness on the part of the health providers to enable them to categorize a given patient, which becomes critical in optimizing communications and management.</p>","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3199-3201"},"PeriodicalIF":2.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10409102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-drug antibodies of IL-17 inhibitors for psoriasis: a systematic review.","authors":"Alexandra Norden,&nbsp;Aislyn Oulee,&nbsp;Leena Munawar,&nbsp;Sogol Stephanie Javadi,&nbsp;George Han,&nbsp;Jashin J Wu","doi":"10.1080/09546634.2022.2114288","DOIUrl":"https://doi.org/10.1080/09546634.2022.2114288","url":null,"abstract":"<p><p>Biologics may elicit the production of anti-drug antibodies (ADAs), the clinical significance of which is not fully understood. ADA development in psoriasis patients on IL-17 inhibitors was evaluated by incidence, impact on efficacy, and relationship with adverse events. We systematically searched PubMed, Cochrane, and Embase databases, identifying 456 references. Seventeen studies met inclusion criteria. ADA incidence was: 0% to 5.5% (secukinumab), 11% to 19.4% (ixekizumab), 0% to 3.3% (brodalumab), and 19% to 39% (bimekizumab). Neutralizing antibody incidence was: 0% to 1.5% (secukinumab), 0% to 3.5% (ixekizumab), and 0% (brodalumab). ADA presence alone with secukinumab, ixekizumab, and bimekizumab did not impact drug efficacy. Brodalumab was the only one of the IL-17 inhibitors, which showed a reduction in efficacy in ADA + patients. In one analysis, high ADA titers to ixekizumab were associated with diminished treatment response. ADAs to secukinumab and bimekizumab were not associated with adverse events. There were limited data on ADAs and safety with ixekizumab or brodalumab. Overall, when monitoring patients on secukinumab, ADAs, titers, and the presence of neutralizing antibodies were not prognostic of outcomes. However, monitoring for ADAs with brodalumab and measuring titers with ixekizumab may be of value clinically.</p>","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3080-3085"},"PeriodicalIF":2.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10414710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brodalumab efficacy in bio-naïve psoriasis patients: real-life experience of 202 subjects up to 48 weeks.","authors":"Luca Mastorino,&nbsp;C Cariti,&nbsp;S Susca,&nbsp;S Boskovic,&nbsp;C Aquino,&nbsp;M Ortoncelli,&nbsp;E Stroppiana,&nbsp;A Verrone,&nbsp;P Dapavo,&nbsp;P Quaglino,&nbsp;Simone Ribero","doi":"10.1080/09546634.2022.2125265","DOIUrl":"https://doi.org/10.1080/09546634.2022.2125265","url":null,"abstract":"Interleukin-17 (IL-17) is central in the pathogenesis of psoriasis (1). Brodalumab was approved in Europe in 2017, and its blockade of IL-17 receptor A provides, in clinical trials, quick onset of action and long-term maintenance of treatment response with a favorable safety profile (2,3). Data regarding real-life use are limited (4–6). We retrospectively assessed efficacy and safety of brodalumab in moderate to severe psoriasis patients attending the Dermatology Clinic of the Turin University Hospital for up to 48weeks. Patients received subcutaneous brodalumab 210mg every 2weeks after the administration of 210mg every week for the first 3weeks. Disease severity at baseline was measured by the Psoriasis Area Severity Index (PASI); PASI improvement of 90% (PASI90) and 100% (PASI100) was recorded at 12, 24, and 48weeks. DLQI response rates were collected at baseline and after 48weeks of treatment. Among 1635 patients on biologics attending our clinic, 202 received brodalumab (Table 1). At week 12, 125 (68%) and 97 (53%) patients achieved PASI90 and PASI100, respectively. At week 24, 93 patients (77%) and 111 (65%) achieved PASI90 and PASI100, respectively. At week 48, 32 patients (78%) achieved PASI90 response, while 39 (64%) had complete clearance. Between baseline and week 48, DLQI improved from a mean of 13.8 to 1.3 (p< .001) and PASI improved from 23.3 to 2.2 (p< .001) respectively). Obesity did not seem to reduce the efficacy or time to onset of action of brodalumab since no difference in efficacy was observed between patients with a BMI above or below 30. No significant differences in efficacy were detected at the different time points between patients with and without joint involvement (Figure 1). Bio-naïve patients improved faster than bio-experienced patients in the first weeks of treatment and at every time point. At week 12, the mean PASI in the bio-naïve population was lower than in the bio-experienced (1.56 vs 2.47; p1⁄4 .045), and more patients achieved PASI 90 and PASI <3 (76% vs 56%; p1⁄4 .004 and 86% vs 69%; p1⁄4 .005). At week 24, more bio-naïve patients than bio-experienced patients achieved PASI90 (84% vs 67%, p1⁄4 .021). Forty-nine patients reported side effects, the most frequent of which were arthralgia (15 patients) in patients without joint involvement at baseline and asthenia (10 patients). Two patients discontinued treatment due to reported side effects, one due to joint pain and one due to a major dental abscess resistant to multiple antibiotic therapies. Brodalumab rapidly improves psoriasis in the first few weeks of treatment, particularly in bio-naïve patients, which is in line with the results of registration studies and previous real-life experience (3,5,6). Performance in bio-experienced patients is also good, as previously reported (5,6). Although not approved in the treatment of psoriatic arthritis, joint involvement does not appear to affect the response to therapy.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3211-3213"},"PeriodicalIF":2.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10433466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics: a systematic review and meta-analysis.","authors":"Špela Šuler Baglama,&nbsp;Irena Peteln,&nbsp;Gregor B E Jemec","doi":"10.1080/09546634.2022.2131298","DOIUrl":"https://doi.org/10.1080/09546634.2022.2131298","url":null,"abstract":"<p><strong>Background: </strong>Inflammation of actinic keratoses (AK) was originally described with systemic 5-fluorouracil, and led to the development of topical fluorouracil. Similar observations using different chemotherapeutics may point to other drugs with a potential for repositioning.</p><p><strong>Objective: </strong>This systematic review aims to evaluate chemotherapeutic agents linked to inflammation-induced cure of AK.</p><p><strong>Methods: </strong>This systematic review was registered in PROSPERO (CRD42022346168) and followed PRISMA guidelines. A comprehensive literature search for eligible original articles written in English and published in peer-reviewed journals until July 13, 2022 was conducted in MEDLINE and Embase.</p><p><strong>Results: </strong>28 articles met inclusion criteria accounting for 36 patients (mean age 68.4 ± 8.3 years) with inflamed AK, exposed to 21 different chemotherapeutic agents - 21/36 (58.3%) received monotherapy and 15/36 (41.7%) received multidrug combinations. Regression was complete in 13/28 (46.4%) and partial in 14/28 (50.0%) of inflamed AK. Cure rates of inflamed AK in multidrug combinations were not superior to monotherapies (<i>p</i> = .252), leading to the observation that the majority of the former (14/15; 93.3%) encompassed one of five chemotherapeutic agents linked to AK inflammation also as a monotherapy.</p><p><strong>Conclusion: </strong>Overall, inflammation partially/completely cured AK in 96.4% of patients (27/28). Taxanes, pemetrexed, and doxorubicin might have the potential for the management of AK.</p>","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3136-3142"},"PeriodicalIF":2.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10433775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}